跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
CIMA-AEMPS
/
SUNLENCA 464 MG SOLUCION INYECTABLE
Approved
STANDARD
SUNLENCA 464 MG SOLUCION INYECTABLE
Gilead Sciences Ireland Unlimited Company
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Sep 16, 2022
Approval ID
e748b9106ebac751
Company
Gilead Sciences Ireland Unlimited Company
Type
Standard
Approval Details
Approval Id
e748b9106ebac751
Drug Cima Aemps Name
SUNLENCA 464 MG SOLUCION INYECTABLE
Register Number
1221671002
Holder Company Name
Gilead Sciences Ireland Unlimited Company
Marketing Company Name
Gilead Sciences S.L.
Holder Company Detail Path
/organization/gilead-sciences-ireland-unlimited-company
Authorization Date
2022-09-16
Dosage Form
SOLUCIÓN INYECTABLE
Dose
464 MG
Route Of Administration
VÍA SUBCUTÁNEA
Prescription Type
Uso Hospitalario
Commercialized
Yes
Company Name
Gilead Sciences Ireland Unlimited Company
Company Detail Path
/organization/gilead-sciences-ireland-unlimited-company
Company Information
Pharmaceutical Company Name
GILEAD SCIENCES IRELAND UNLIMITED COMPANY
Country Name
Ireland
City Name
carrigtwohill,country_ie
Address
Ida Business & Technology Park
Active Ingredients
LENACAPAVIR SODIO
315,4 mg/ml
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Sep 16, 2022
Approval ID
e748b9106ebac751
Type
Standard
Back to CIMA-AEMPS Approvals